CRISPR Therapeutics AG is a leading biopharmaceutical company focused on the development of CRISPR based therapeutics using CRISPR/Cas9 technology. The company advances a portfolio of programs across four core franchises: hemoglobinopathies, in vivo gene editing, chimeric antigen receptor T cell (CAR T) therapies, and regenerative medicine.

CRISPR Therapeutics generates revenue primarily through collaboration agreements that include upfront payments, milestone payments, and royalties on net product sales. Key partnerships involve Vertex Pharmaceuticals for hemoglobinopathies and diabetes, Sirius Therapeutics for siRNA based anticoagulants, and Eli Lilly for oncology CAR T programs. The company also earns revenue from the commercialization of CASGEVY, the first approved CRISPR based therapy for sickle cell disease and transfusion dependent beta thalassemia, which is co developed and co commercialized with Vertex.

The company operates through the following segments: hemoglobinopathies, in vivo approaches, CAR T, and regenerative medicine.

• Hemoglobinopathies: This segment focuses on CASGEVY, an ex vivo CRISPR/Cas9 gene edited cell therapy for sickle cell disease and transfusion dependent beta thalassemia, with approvals in multiple countries and ongoing research on targeted conditioning and in vivo hematopoietic stem cell editing.

• In vivo approaches: This segment leverages lipid nanoparticle delivery for liver directed gene editing programs such as CTX310 targeting ANGPTL3 for cardiovascular disease, plus siRNA programs like CTX611 targeting Factor XI for anticoagulation, and other preclinical programs for hypertension, alpha 1 antitrypsin deficiency, and lipoprotein(a).

• CAR T: This segment develops next generation allogeneic CAR T candidates such as zogocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune indications including systemic lupus erythematosus and oncology indications including relapsed or refractory B cell malignancies, manufactured at its internal GMP manufacturing facility.

• Regenerative medicine: This segment advances a deviceless beta cell replacement product candidate CTX213 derived from induced pluripotent stem cells for type 1 diabetes, incorporating immune evasive gene edits, and has licensed certain CRISPR intellectual property to Vertex for diabetes applications.

CRISPR Therapeutics holds a leading position in the gene editing industry as the developer of the first approved CRISPR based therapy, CASGEVY. The company competes with firms such as Editas Medicine, Intellia Therapeutics, Beam Therapeutics, and Allogene Therapeutics, while maintaining advantages through its pioneering CRISPR/Cas9 platform, broad intellectual property portfolio, strategic collaborations with Vertex and Sirius, and internal manufacturing capabilities that support scalable production of cell and genetic therapies.

The company serves patients with severe sickle cell disease, transfusion dependent beta thalassemia, cardiovascular diseases such as hypercholesterolemia and hypertriglyceridemia, autoimmune disorders including systemic lupus erythematosus, and individuals with type 1 diabetes. Its therapies are developed and commercialized through partnerships with pharmaceutical companies that provide access to broader patient populations.